Acalabrutinib + Chemotherapy for Waldenstrom's Macroglobulinemia
(BRAWM Trial)
Trial Summary
What is the purpose of this trial?
This trial tests a combination of two established drugs and one new drug in untreated patients with a specific type of blood cancer. The treatment works by killing cancer cells, boosting the immune system, and blocking growth signals.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop all current medications, but you cannot be on warfarin or proton pump inhibitors. If you are on proton pump inhibitors, you can switch to H2-receptor antagonists or antacids 7 days before starting the trial.
What data supports the effectiveness of the drug combination Acalabrutinib, Bendamustine, and Rituximab for treating Waldenstrom's Macroglobulinemia?
Is the combination of Acalabrutinib and chemotherapy safe for treating Waldenstrom's Macroglobulinemia?
Acalabrutinib, a targeted cancer drug, has been shown to have a tolerable safety profile in treating B-cell cancers, with most side effects being mild, like headaches and diarrhea. Bendamustine, another drug used in combination therapies, was well tolerated in studies, with no unexpected toxicities. Overall, these treatments have been generally safe in clinical trials for similar conditions.13567
What makes the drug Acalabrutinib + Chemotherapy unique for treating Waldenstrom's Macroglobulinemia?
Acalabrutinib combined with Bendamustine and Rituximab offers a novel approach for treating Waldenstrom's Macroglobulinemia by targeting specific pathways in cancer cells, potentially providing a more effective treatment option compared to traditional therapies. This combination leverages the unique mechanisms of each drug, such as Acalabrutinib's ability to inhibit Bruton's tyrosine kinase (a protein involved in cancer cell growth), which may enhance the overall treatment efficacy.89101112
Research Team
Neil L Berinstein, MD
Principal Investigator
Sunnybrook Research Institute
Eligibility Criteria
This trial is for adults with untreated Waldenstrom's Macroglobulinemia, a type of lymphoma. Participants must have a life expectancy over 6 months, be willing to use effective birth control methods, and have adequate organ function. They should not have had previous systemic treatments for the disease (except certain allowed therapies) and must be able to comply with study requirements.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive bendamustine and rituximab for 6 cycles, and acalabrutinib for 1 year
Follow-up
Participants are monitored for safety and effectiveness after treatment, with extended follow-up by telephone
Treatment Details
Interventions
- Acalabrutinib
- Bendamustine
- Rituximab
Acalabrutinib is already approved in United States, European Union for the following indications:
- Mantle cell lymphoma
- Chronic lymphocytic leukemia
- Small lymphocytic lymphoma
- Chronic lymphocytic leukemia
- Small lymphocytic lymphoma
- Mantle cell lymphoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sunnybrook Health Sciences Centre
Lead Sponsor
AstraZeneca
Industry Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology